古塞奇尤单抗(抗白介素23单克隆抗体)治疗掌跖脓疱病的疗效与安全性:一项随机临床试验
这项双盲、随机、安慰剂对照、平行组、24周试验在日本的11个中心进行,纳入49例对常规治疗应答不足的中重度掌跖脓疱病患者,按1:1随机接受古塞奇尤单抗200mg皮下注射或安慰剂(第0周和第4周)。第16周时,古塞奇尤单抗组掌跖脓疱病严重程度指数总分较基线的改善显著优于安慰剂组(最小二乘均值差-1.5;95%CI -2.9至-0.2;P=0.03);不良事件发生率两组相当,未出现重大安全性问题。作者认为,靶向IL-23可能为掌跖脓疱病提供一种安全且有用的治疗选择。
要点
- 古塞奇尤单抗200mg皮下注射(第0、4周)治疗中重度掌跖脓疱病,第16周严重程度指数总分改善显著优于安慰剂(P=0.03)。
- 第16周掌跖脓疱病面积和严重程度指数评分及50%改善比例均显著优于安慰剂(P=0.009)。
- 古塞奇尤单抗组与安慰剂组治疗中出现的不良事件发生率相当(76% vs 75%),未出现重大安全性问题。
核心结论
- 靶向IL-23及其相关免疫级联反应的古塞奇尤单抗可能是治疗掌跖脓疱病的一种安全且有用的治疗选择。
研究设计与样本
- 双盲、随机、安慰剂对照、平行组、24周试验,于2013年5月14日至2014年9月27日在日本11个中心进行。
- 纳入49例对常规治疗应答不足的中重度掌跖脓疱病患者,按1:1随机接受古塞奇尤单抗200mg皮下注射或匹配安慰剂,在第0周和第4周给药。
主要发现
- 第16周时,古塞奇尤单抗组掌跖脓疱病严重程度指数总分(主要终点)较基线平均(SD)改善-3.3(2.43),安慰剂组为-1.8(2.09),最小二乘均值差-1.5(95%CI -2.9至-0.2;P=0.03)。
- 第16周时,掌跖脓疱病面积和严重程度指数评分的最小二乘均值差为-5.65(95%CI -9.80至-1.50;P=0.009),达到50%评分改善的患者比例差异为39.2(95%CI 14.0-64.3;P=0.009)。
- 古塞奇尤单抗组医师总体评估评分≤1的患者比例在数值上高于安慰剂组,古塞奇尤单抗组疗效评分改善维持至第24周。
- 第4周和第16周观察到血清IL-17A和IL-17F细胞因子水平较基线显著降低。
- 古塞奇尤单抗组治疗中出现的不良事件发生率为19/25例(76%),安慰剂组为18/24例(75%);常见不良事件包括鼻咽炎14例(29%)、头痛3例(6%)、接触性皮炎3例(6%)和注射部位红斑3例(6%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Palmoplantar pustulosis (PPP) is a recalcitrant skin disease with no biologics currently approved for treatment. The involvement of interleukin 23 (IL-23) and cytokines of the type 17 helper T cell lineage in the pathogenesis of PPP has been recently postulated. OBJECTIVE: To evaluate the efficacy and safety of guselkumab, an anti-IL-23 monoclonal antibody, in Japanese patients with PPP. DESIGN, SETTING, AND PARTICIPANTS: This double-blind, randomized, placebo-controlled, parallel-group, 24-week trial was conducted between May 14, 2013, and September 27, 2014, at 11 centers in Japan. Participants were patients with moderate to severe PPP that did not respond adequately to conventional treatments. INTERVENTIONS: Patients were randomized 1:1 to receive guselkumab, 200 mg, by subcutaneous injection or matching placebo at weeks 0 and 4. MAIN OUTCOMES AND MEASURES: Changes in total scores of skin-related outcomes from baseline at the end of week 16 (primary clinical cutoff) and through week 24 were measured. Serum biomarker analyses were performed at baseline, week 4, and week 16, and safety was monitored through week 24. RESULTS: Of 49 randomized patients (35 [71%] women; median [range] age, 52 [28-77] years), 41 completed the study at week 24. Mean (SD) PPP severity index total scores (primary end point) improved significantly from baseline in guselkumab-treated patients (-3.3 [2.43]) vs placebo (-1.8 [2.09]) (least squares mean difference, -1.5; 95% CI, -2.9 to -0.2; P = .03). At week 16, PPP area and severity index scores (least squares mean difference, -5.65; 95% CI, -9.80 to -1.50; P = .009) and proportion of patients achieving 50% reduction in these scores (difference in proportion, 39.2; 95% CI, 14.0-64.3; P = .009) improved significantly. A numerically higher proportion of patients had a physician's global assessment score of 1 or less in the guselkumab group vs placebo. Improvement in efficacy scores was maintained through week 24 in the guselkumab group. Significant reductions from baseline in serum IL-17A and IL-17F cytokine levels were observed at weeks 4 and 16. Frequency of treatment-emergent adverse events was comparable between the guselkumab group (19 of 25 patients [76%]) and the placebo group (18 of 24 patients [75%]). Frequent adverse effects included nasopharyngitis (14 patients [29%]), headache (3 patients [6%]), contact dermatitis (3 patients [6%]), and injection site erythema (3 patients [6%]). No major safety concerns emerged during the study. CONCLUSIONS AND RELEVANCE: Targeting IL-23 and its associated immune cascade with guselkumab may be a safe and useful therapeutic option for treatment of PPP. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01845987.
引用
- Terui T, Kobayashi S, Okubo Y, et al. Efficacy and Safety of Guselkumab, an Anti-interleukin 23 Monoclonal Antibody, for Palmoplantar Pustulosis: A Randomized Clinical Trial. JAMA Dermatol. 2018. PMID: 29417135. doi:10.1001/jamadermatol.2017.5937
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。